Regulatory rejection flurry does not make a storm
Fears of heightened scrutiny by the FDA will be calmed by a look at historic rates of complete response letters.
Shedding light on Intercept’s opaque disclosure
Intercept’s woes have continued as a possible new liver toxicity signal was buried in a regulatory filing. What could this mean?
